Hans-Georg Wirsching

Dr. Hans-Georg Wirsching


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016
Verified
Book Chapter
Closed access
HWHans-Georg Wirsching
Hans-Georg Wirsching
EGEvanthia Galanis
Evanthia Galanis
MWMichael Weller
Michael Weller

10 April 2018 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
HWHans-Georg Wirsching
Hans-Georg Wirsching
Ghazaleh TabatabaiGhazaleh Tabatabai
Ghazaleh Tabatabai
URU. Roelcke
U. Roelcke
AHA.F. Hottinger
A.F. Hottinger
FJF. Jörger
F. Jörger
MWMichael Weller
Michael Weller
The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT → TMZ) did not prolong overall survival (OS) in patients with newly diagnosed glioblastoma in phase III trials. Elderly and frail patients are underrepresented in clinical trials, but early reports suggested preferential benefit in this population. ARTE was a 2 : 1 randomized, multi-center, open-label, non-comparative phase II trial of hypofractionated RT (40 Gy in 15 fractions) with bevacizumab (10 mg/kg×14 days) (arm A, N = 50) or without bevacizumab (arm B, N = 25) in patients with newly diagnosed glioblastoma aged ≥65 years. The primary objective was to obtain evidence for prolongation of median OS by the addition of bevacizumab to RT. Response was assessed by RANO criteria. Quality of life (QoL) was monitored by the EORTC QLQ-C30/BN20 modules. Exploratory studies included molecular subtyping by 450k whole methylome and gene expression analyses. Median PFS was longer in arm A than in arm B (7.6 and 4.8 months, P = 0.003), but OS was similar (12.1 and 12.2 months, P = 0.77). Clinical deterioration was delayed and more patients came off steroids in arm A. Prolonged PFS in arm A was confined to tumors with the receptor tyrosine kinase (RTK) I methylation subtype (HR 0.25, P = 0.014) and proneural gene expression (HR 0.29, P = 0.025). In a Cox model of OS controlling for established prognostic factors, associations with more favorable outcome were identified for age <70 years (HR 0.52, P = 0.018) and Karnofsky performance score 90%–100% (HR 0.51, P = 0.026). Including molecular subtypes into that model identified an association of the RTK II gene methylation subtype with inferior OS (HR 1.73, P = 0.076). Efficacy outcomes and exploratory analyses of ARTE do not support the hypothesis that the addition of bevacizumab to RT generally prolongs survival in elderly glioblastoma patients. Molecular biomarkers may identify patients with preferential benefit from bevacizumab. NCT01443676.

15 January 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MMMaximilian Mastall
Maximilian Mastall
PRPatrick Roth
Patrick Roth
ABAndrea Bink
Andrea Bink
AMAngela Fischer Maranta
Angela Fischer Maranta
HLHeinz Läubli
Heinz Läubli
HWHans-Georg Wirsching
Hans-Georg Wirsching
Background: Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma. Methods/design: GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland. Trial registration: NCT05664464. Registered 23 December 2022.

16 April 2021 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
ARAmanda Randles
Amanda Randles
HWHans-Georg Wirsching
Hans-Georg Wirsching
JDJamie Dean
Jamie Dean
YCYu-Kang Cheng
Yu-Kang Cheng
SESamuel Jay Emerson
Samuel Jay Emerson
FMFranziska Michor
Franziska Michor
Glioblastoma stem-like cells dynamically transition between a chemoradiation-resistant state and a chemoradiation-sensitive state. However, physical barriers in the tumour microenvironment restrict the delivery of chemotherapy to tumour compartments that are distant from blood vessels. Here, we show that a massively parallel computational model of the spatiotemporal dynamics of the perivascular niche that incorporates glioblastoma stem-like cells and differentiated tumour cells as well as relevant tissue-level phenomena can be used to optimize the administration schedules of concurrent radiation and temozolomide—the standard-of-care treatment for glioblastoma. In mice with platelet-derived growth factor (PDGF)-driven glioblastoma, the model-optimized treatment schedule increased the survival of the animals. For standard radiation fractionation in patients, the model predicts that chemotherapy may be optimally administered about one hour before radiation treatment. Computational models of the spatiotemporal dynamics of the tumour microenvironment could be used to predict tumour responses to a broader range of treatments and to optimize treatment regimens.

11 May 2021 in Brain
Verified
Journal Article
Closed access
PDF file
MMMaximilian Mastall
Maximilian Mastall
FWFabian Wolpert
Fabian Wolpert
DGDorothee Gramatzki
Dorothee Gramatzki
LILukas Imbach
Lukas Imbach
DBDenise Becker
Denise Becker
HWHans-Georg Wirsching
Hans-Georg Wirsching
Pro-tumorigenic electrochemical synapses between neurons and brain tumor cells in pre-clinical studies suggest unfavorable effects of epilepsy on patient survival. We investigated associations of epilepsy and survival in three cohorts of brain tumor patients (meningioma, glioblastoma, brain metastases). Cohorts were segregated into three groups for comparative analyses: (i) no epilepsy, (ii) epilepsy without status epilepticus and (iii) status epilepticus. Status epilepticus was considered a surrogate of extensive neuronal hyperexcitability. Main outcome was progression-free survival (meningioma) and overall survival (glioblastoma and brain metastases), adjusted for established prognostic factors and onset of epilepsy by time-dependent multivariate Cox modeling. The primary analysis population comprised 1792 patients (742 meningioma, 249 glioblastoma, 801 brain metastases). Epilepsy was associated with favorable prognostic factors. On multivariate analyses, status epilepticus was however associated with inferior overall survival of patients with glioblastoma (status epilepticus vs no epilepsy multivariate HR 3.72, CI 1.78–7.76, P<0.001) and brain metastases (status epilepticus vs no epilepsy HR 2.30, CI 1.10–4.79, P=0.026). Among brain metastases patients, but not among patients with meningioma or glioblastoma, epilepsy was similarly associated with inferior overall survival (epilepsy vs no epilepsy HR 2.16, CI 1.60–2.93, P<0.001). We conclude that epilepsy may convey inferior survival of patients with malignant brain tumors.

1 January 2021 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HWHans-Georg Wirsching
Hans-Georg Wirsching
URUlrich Roelcke
Ulrich Roelcke
JWJonathan Weller
Jonathan Weller
THTom Hundsberger
Tom Hundsberger
AHAndreas Felix Hottinger
Andreas Felix Hottinger
MWMichael Weller
Michael Weller
Purpose: To explore a prognostic or predictive role of magnetic resonance imaging (MRI) and O-(2-18F-fluoroethyl)-L-tyrosine (18FET) positron emission tomography (PET) parameters for outcome in the randomized multi-center trial ARTE that compared bevacizumab plus radiotherapy with radiotherpay alone in elderly patients with glioblastoma. Experimental Design: Patients with isocitrate dehydrogenase wild-type glioblastoma aged 65 years or older were included in this post-hoc analysis. Tumor volumetric and apparent diffusion coefficient (ADC) analyses of serial MRI scans from 67 patients and serial 18FET-PET tumor-to-brain intensity ratios (TBR) from 31 patients were analyzed blinded for treatment arm and outcome. Multivariate Cox regression analysis was done to account for established prognostic factors and treatment arm. Results: Overall survival benefit from bevacizumab plus radiotherapy compared to radiotherapy alone was observed for larger pre-treatment MRI contrast-enhancing tumor (hazard ratio [HR] per cm3 0.94, 95% confidence interval [CI] 0.89-0.99) and for higher ADC (HR 0.18, CI 0.05-0.66). Higher 18FET-TBR on pre-treatment PET scans was associated with inferior overall survival in both arms. Response assessed by standard MRI-based RANO criteria was associated with overall survival in the bevacizumab plus radiotherapy arm by trend only (p=0.09). High 18FET-TBR of non-contrast-enhancing tumor portions during bevacizumab therapy was associated with inferior overall survival on multivariate analysis (HR 5.97, CI 1.16-30.8). Conclusion: Large pre-treatment contrast-enhancing tumor mass and higher ADC identify patients who may experience a survival benefit from bevacizumab plus radiotherapy. Persistent 18FET-PET signal of no longer contrast-enhancing tumor after concomitant bevacizumab plus radiotherapy suggests pseudoresponse and predicts poor outcome. Trial registration: NCT01443676.